Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome
- VernacularTitle:骨髓增生异常综合征的异基因造血干细胞移植
- Author:
Daihong LIU
;
Xiaojun HUANG
- Publication Type:Journal Article
- Keywords:
hematopoietic stem cell transplantation;
allogeneic;
myelodysplastic syndrome
- From:
Chinese Journal of Practical Internal Medicine
2001;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
The indications for patients with Myelodysplastic Syndrome (MDS) to receive allogeneic hematopoietic stem cell transplantation (Allo-HCT) are:intermediate risk-2 and high risk groups according to IPSS,and intermediate risk-1 group with poor karyotype,severe multilineage cytopenia or infusion-dependent.Constant follow-up and evaluation is important for therapeutic decision.Unrelated or related haploidentical donor could be an alternative in case of absence of identical sibling donor.Remission through chemotherapy before the transplantation is recommended in patients with advanced MDS who receive reduced-intensity conditioning.Demethylation drugs followed by Allo-HCT do not show additional transplantation-related toxicity,whose efficiency remains to be determined.
